Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis

BACKGROUND: To evaluate the value of new therapies for non-small cell lung cancer (NSCLC), it is necessary to understand overall survival (OS) rates associated with previous standard therapies and how these rates have evolved over time. METHODS: We retrospectively analyzed data from patients enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Ryan N., Zhang, Yiduo, Seal, Brian, Ryan, Kellie, Yong, Candice, Darilay, Annie, Ramsey, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132866/
https://www.ncbi.nlm.nih.gov/pubmed/32248816
http://dx.doi.org/10.1186/s12885-020-06734-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132866/
https://www.ncbi.nlm.nih.gov/pubmed/32248816
http://dx.doi.org/10.1186/s12885-020-06734-3

Ejemplares similares